Literature DB >> 19158248

Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes.

Huabiao Chen1, Alicja Piechocka-Trocha, Toshiyuki Miura, Mark A Brockman, Boris D Julg, Brett M Baker, Alissa C Rothchild, Brian L Block, Arne Schneidewind, Tomohiko Koibuchi, Florencia Pereyra, Todd M Allen, Bruce D Walker.   

Abstract

Defining the antiviral efficacy of CD8 T cells is important for immunogen design, and yet most current assays do not measure the ability of responses to neutralize infectious virus. Here we show that human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte (CTL) clones and cell lines derived from infected persons and targeting diverse epitopes differ by over 1,000-fold in their ability to retard infectious virus replication in autologous CD4 T cells during a 7-day period in vitro, despite comparable activity as assessed by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay. Cell lines derived from peripheral blood mononuclear cells stimulated in vitro with peptides representing targeted Gag epitopes consistently neutralized HIV better than Env-specific lines from the same person, although ineffective inhibition of virus replication is not a universal characteristic of Env-specific responses at the clonal level. Gag-specific cell lines were of higher avidity than Env-specific lines, although avidity did not correlate with the ability of Gag- or Env-specific lines to contain HIV replication. The greatest inhibition was observed with cell lines restricted by the protective HLA alleles B*27 and B*57, but stimulation with targeted Gag epitopes resulted in greater inhibition than did stimulation with targeted Env epitopes even in non-B*27/B*57 subjects. These results assessing functional virus neutralization by HIV-specific CD8 T cells indicate that there are marked epitope- and allele-specific differences in virus neutralization by in vitro-expanded CD8 T cells, a finding not revealed by standard IFN-gamma ELISPOT assay currently in use in vaccine trials, which may be of critical importance in immunogen design and testing of candidate AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158248      PMCID: PMC2655558          DOI: 10.1128/JVI.02073-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Authors:  Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors
Journal:  Nat Immunol       Date:  2002-10-07       Impact factor: 25.606

Review 2.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.

Authors:  Bradley H Edwards; Anju Bansal; Steffanie Sabbaj; Janna Bakari; Mark J Mulligan; Paul A Goepfert
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Evaluation of antigen-specific responses using in vitro enriched T cells.

Authors:  N Jones; D Agrawal; M Elrefaei; A Hanson; V Novitsky; J T Wong; Huyen Cao
Journal:  J Immunol Methods       Date:  2003-03-01       Impact factor: 2.303

6.  Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.

Authors:  Todd M Allen; Marcus Altfeld; Xu G Yu; Kristin M O'Sullivan; Mathias Lichterfeld; Sylvie Le Gall; Mina John; Bianca R Mothe; Paul K Lee; Elizabeth T Kalife; Daniel E Cohen; Kenneth A Freedberg; Daryld A Strick; Mary N Johnston; Alessandro Sette; Eric S Rosenberg; Simon A Mallal; Philip J R Goulder; Christian Brander; Bruce D Walker
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL.

Authors:  Otto O Yang; Phuong T Nguyen Sarkis; Alicja Trocha; Spyros A Kalams; R Paul Johnson; Bruce D Walker
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

8.  Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.

Authors:  Stephen A Migueles; Christine M Osborne; Cassandra Royce; Alex A Compton; Rohan P Joshi; Kristin A Weeks; Julia E Rood; Amy M Berkley; Jonah B Sacha; Nancy A Cogliano-Shutta; Margaret Lloyd; Gregg Roby; Richard Kwan; Mary McLaughlin; Sara Stallings; Catherine Rehm; Marie A O'Shea; JoAnn Mican; Beverly Z Packard; Akira Komoriya; Sarah Palmer; Ann P Wiegand; Frank Maldarelli; John M Coffin; John W Mellors; Claire W Hallahan; Dean A Follman; Mark Connors
Journal:  Immunity       Date:  2008-12-08       Impact factor: 31.745

9.  Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

Authors:  M M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; David R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection.

Authors:  Rika Draenert; Sylvie Le Gall; Katja J Pfafferott; Alasdair J Leslie; Polan Chetty; Christian Brander; Edward C Holmes; Shih-Chung Chang; Margaret E Feeney; Marylyn M Addo; Lidia Ruiz; Danni Ramduth; Prakash Jeena; Marcus Altfeld; Stephanie Thomas; Yanhua Tang; Cori L Verrill; Catherine Dixon; Julia G Prado; Photini Kiepiela; Javier Martinez-Picado; Bruce D Walker; Philip J R Goulder
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  59 in total

1.  Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.

Authors:  Olusimidele T Akinsiku; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

2.  Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.

Authors:  Elizabeth Connick; Ronald J Bosch; Evgenia Aga; Rick Schlichtemeier; Lisa M Demeter; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2011-09-01       Impact factor: 3.731

3.  Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Authors:  Stephanie A Freel; Ralph A Picking; Guido Ferrari; Haitao Ding; Christina Ochsenbauer; John C Kappes; Jennifer L Kirchherr; Kelly A Soderberg; Kent J Weinhold; Coleen K Cunningham; Thomas N Denny; John A Crump; Myron S Cohen; Andrew J McMichael; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

4.  Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses.

Authors:  Zaza M Ndhlovu; Jacqueline Proudfoot; Kevin Cesa; Donna Marie Alvino; Ashley McMullen; Seanna Vine; Eleni Stampouloglou; Alicja Piechocka-Trocha; Bruce D Walker; Florencia Pereyra
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

5.  Rapid, efficient functional characterization and recovery of HIV-specific human CD8+ T cells using microengraving.

Authors:  Navin Varadarajan; Douglas S Kwon; Kenneth M Law; Adebola O Ogunniyi; Melis N Anahtar; James M Richter; Bruce D Walker; J Christopher Love
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-21       Impact factor: 11.205

6.  Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.

Authors:  Kathryn E Stephenson; Hualin Li; Bruce D Walker; Nelson L Michael; Dan H Barouch
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

7.  Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.

Authors:  Otto O Yang; Eric S Daar; Hwee L Ng; Roger Shih; Beth D Jamieson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-18       Impact factor: 2.205

8.  The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.

Authors:  Zaza M Ndhlovu; Eleni Stampouloglou; Kevin Cesa; Orestes Mavrothalassitis; Donna Marie Alvino; Jonathan Z Li; Shannon Wilton; Daniel Karel; Alicja Piechocka-Trocha; Huabiao Chen; Florencia Pereyra; Bruce D Walker
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

Review 9.  HIV-specific CD8⁺ T cells and HIV eradication.

Authors:  R Brad Jones; Bruce D Walker
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

10.  CD8+ TCR Bias and Immunodominance in HIV-1 Infection.

Authors:  Henrik N Kløverpris; Reuben McGregor; James E McLaren; Kristin Ladell; Mikkel Harndahl; Anette Stryhn; Jonathan M Carlson; Catherine Koofhethile; Bram Gerritsen; Can Keşmir; Fabian Chen; Lynn Riddell; Graz Luzzi; Alasdair Leslie; Bruce D Walker; Thumbi Ndung'u; Søren Buus; David A Price; Philip J Goulder
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.